Chemotherapy of schistosomiasis: An update

Parasitology Today

Volumn 14, Issue 10, 1998, Pages 418-422

  Cioli, D ^a  

^a Institutes of Human Anatomy and Cell Biology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AMOSCANATE; ANTIMONY DERIVATIVE; ARTEETHER; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; CYCLOPHILIN; CYCLOSPORIN A; EMETINE; HYCANTHONE; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LUCANTHONE; MECLONAZEPAM; METRIFONATE; NITROFURAN DERIVATIVE; OLTIPRAZ; OXAMNIQUINE; PRAZIQUANTEL; RECOMBINANT PROTEIN; SESQUITERPENE LACTONE; TUBERCIDIN;

DRUG RESISTANCE; HUMAN; NONHUMAN; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 0031796259     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(98)01323-4     Document Type: Review

References (51)

1. Cioli D., Pica-Mattoccia L., Archer S. Antischistosomal drugs: past, present . and future? Pharmacol. Ther. 68:1995;35-85.
2. W.H.O. (1997) Seventh report of the WHO Expert Committee. WHO Tech. Rep. Ser. 867, WHO.
3. Chappell L.H., Thomson A.W. Studies on the action of cyclosporin A against Schistosoma mansoni and other parasitic infections. Transpl. Proc. 20:1988;291-297.
4. Bout D.T., Deslée D., Capron A. Protection against schistosomiasis produced by cyclosporin A. Am. J. Trop. Med. Hyg. 33:1984;185-186.
5. Argaet V.P., Mitchell G.F. Cyclophilin of Schistosoma japonicum. J. Parasitol. 78:1992;660-664.
6. Klinkert M.Q.et al. Characterization of a Schistosoma mansoni cDNA encoding a B-like cyclophilin and its expression in Escherichia coli. Mol. Biochem. Parasitol. 75:1995;99-111.
7. Klinkert M.Q.et al. Sequence conservation of schistosome cyclophilins. Mol. Biochem. Parasitol. 81:1996;239-242.
8. Bugli F.et al. Expression cloning and biochemical characterization of recombinant cyclophilin proteins from Schistosoma mansoni. Protein Expres. Purif. 12:1998;340-346.
9. Xiao S.H., Catto B.A. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob. Agents Chemother. 33:1989;1557-1562.
10. Araujo N., Kohn A., Katz N. Activity of the artemether in experimental schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz. 86(Suppl. 2):1991;185-188.
11. Xiao S.H.et al. Experimental studies on early treatment of schistosomal infection with artemether. Southeast Asian J. Trop. Med. Public Health. 26:1995;306-318.
12. Xiao S.H.et al. Effect of early treatment of artemether against schistosomiasis in mice. Ching Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih. 12:1994;7-12.
13. Li S.et al. Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin. Med. J. 109:1996;848-853.
14. Coelho P.M.Z., Pereira L.H., de Mello R.T. Antischistosomal activity of acridanone-hydrazones in Cebus monkeys experimentally infected with the SJ strain of Schistosoma mansoni. Rev. Soc. Bras. Med. Trop. 28:1995;179-183.
15. Pereira L.H.et al. Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz. 90:1995;425-428.
16. Metwally A.et al. Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of S. mansoni in mice. Arzneimittelforschung. 47:1997;975-979.
17. Penido M.L.O.et al. Schistosomicidal activity of alkylaminooctanethiosulphuric acids. Mem. Inst. Oswaldo Cruz. 89:1994;595-602.
18. Penido M.L.O.et al. Metabolism by Schistosoma mansoni of a new schistosomicide: 2-[(1-methylpropyl)-amino]-1-octanesulphuric acid. Parasitology. 111:1995;177-185.
19. Foster J.M.et al. Effect of insect-growth disrupting amines and amides on Schistosoma mansoni in vitro. J. Parasitol. 82:1996;340-343.
20. McTigue M.A., Williams D.R., Tainer J.A. Crystal structure of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. J. Mol. Biol. 246:1995;21-27.
21. Milhon J.L.et al. Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action. Exp. Parasitol. 87:1997;268-274.
22. Day T.A., Bennett J.L., Pax R.A. Praziquantel: the enigmatic antiparasitic. Parasitol. Today. 8:1992;342-344.
23. Redman C.A.et al. Praziquantel: an urgent and exciting challenge. Parasitol. Today. 12:1996;14-20.
24. Nechay B.R., Hillman G.R., Dotson M.J. Properties and drug sensitivity of adenosine triphosphatases from Schistosoma mansoni. J. Parasitol. 66:1980;596-600.
25. 2+)-ATPases of Schistosoma mansoni. Life Sci. 60:1997;289-294.
26. Sabah A.A.et al. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp. Parasitol. 60:1985;348-354.
27. Tanaka Hall T.M., Joseph G.T., Strand M. Schistosoma mansoni: molecular cloning and sequencing of the 200-kDa chemotherapeutic target antigen. Exp. Parasitol. 80:1995;242-249.
28. Flisser A.et al. Effect of praziquantel on protozoan parasites. Lancet. 345:1995;316-317.
29. Lui J., Stewart J.T. High-performance liquid chromatography determination of praziquantel enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and disc solid-phase extraction. J. Chromatogr. B Biomed. Sci. Appl. 692:1997;141-147.
30. Jabor V.A., Rocha G.M., Bonato P.S. Enantioselective analysis of praziquantel in plasma samples. J. Chromatogr. B Biomed. Sci. Appl. 696:1997;307-311.
31. Kiec-Kononowicz K., Farghaly Z.S., Blaschke G. Synthesis and properties of cis- and trans-4-hydroxypraziquantel. Arch. Pharmacol. 324:1991;235-237.
32. Stelma F.F.et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 53:1995;167-170.
33. Gryseels B.et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop. Geogr. Med. 46:1994;209-219.
34. Guissé F.et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in northern Senegal. Am. J. Trop. Med. Hyg. 56:1997;511-514.
35. Stelma F.F.et al. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J. Infect. Dis. 176:1997;304-307.
36. Editorial (1992) Praziquantel shows unexpected failure in recent schistosomiasis outbreak. TDR News 41, 1-2.
37. Letters to the Editor (1993) Praziquantel in Senegal schistosomiasis outbreak. TDR News 42, 10-12.
38. Brown P. Deadly worm may be turning drug-resistant. New Sci. 144:1994;4.
39. Gönnert R., Andrews P. Praziquantel, a new broad-spectrum antischistosomal agent. Z. Parasitenk. 52:1977;129-150.
40. Sabah A.A.et al. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 61:1986;294-303.
41. Sabah A.A.et al. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp. Parasitol. 60:1985;348-354.
42. Picquet M.et al. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans. R. Soc. Trop. Med. Hyg. 92:1998;90-93.
43. Ismail M.et al. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg. 55:1996;214-218.
44. Bennett J.L.et al. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp. Parasitol. 87:1997;260-267.
45. Herwaldt B.L.et al. Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin. Infect. Dis. 20:1995;309-315.
46. Murray-Smith S.Q.et al. A case of refractory schistosomiasis. Med. J. Aust. 165:1996;458.
47. Chidiac C.et al. Echecs au praziquantel dans le traitement des bilharzioses: intérêt de la biopsie de muqueuse rectale et du suivi prolongé. Méd. Mal. Inf. 5:1986;380-384.
48. Ajana F.et al. La bilharziose humaine à Schistosoma mekongi. Problèmes diagnostiques et thérapeutiques. Méd. Mal. Inf. 3:1986;141-146.
49. Fallon P.G., Doenhoff M.J. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 51:1994;83-88.
50. Fallon P.G.et al. Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 53:1995;61-62.
51. Fallon P.G.et al. Schistosoma mansoni: maturation rate and drug susceptibility of different geographical isolates. Exp. Parasitol. 86:1997;29-36.